Food and Drug Administration (FDA) and Clarivate Extend Material Transfer Agreement for Three Additional Years
Portfolio Pulse from Benzinga Newsdesk
Clarivate Plc (NYSE:CLVT) has extended its Material Transfer Agreement (MTA) with the FDA for an additional three years, ensuring continued agency-wide access to OFF-X™, which provides integrated preclinical toxicity, clinical, and post-marketing adverse event data.
May 23, 2023 | 7:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clarivate Plc's extension of the Material Transfer Agreement with the FDA for three more years ensures continued access to OFF-X™, potentially benefiting the company's revenue and reputation.
The extension of the Material Transfer Agreement between Clarivate Plc and the FDA ensures continued access to OFF-X™, which is a valuable resource for the agency. This partnership extension demonstrates the FDA's trust in Clarivate's services and could lead to increased revenue and an enhanced reputation for the company. As a result, the stock price is likely to go up in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100